Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Group 1 - Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases, including oncology and obesity [3] - The company has granted an equity inducement award to a new employee as part of its 2022 Employment Inducement Award Plan, which was approved by the Compensation Committee [1][2] - The equity award consists of options to purchase 20,000 shares of common stock at an exercise price of $8.10, with a vesting period of four years [2] Group 2 - Terns' pipeline includes three clinical stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [3]